

2019 Inpatient Data- All sources other than urine

For use by providers within DH Clinics only. Please do not share with Pharmaceutical Representatives.



Organisms
Per CLSI guidelines, there should be 30 or more isolates to be considered statistically adequate for selecting antibiotics for treatment.

	Number of Isolates	Penicillin	Ampicillin	Ox/Nafcillin	Ampicillin/Sulbactam	Piperacillin/Tazo	Cefazolin (first)	Cefuroxime (second)	Ceftazidime (third)	Ceftriaxone (third)	Cefepime (fourth)	Aztreonam	Meropenem	Daptomycin	Linezolid	Gentamicin	Tobramycin	Vancomycin	Clindamycin	Erythromycin	Tetracycline	Trimethoprim-sulfa	Ciprofloxacin	Levofloxacin
GRAM POSITIVES																								
<i>Staphylococcus aureus -MSSA</i>	444			100	100		100			100			100			99		100	77	67	95	99	89	92
<i>Staphylococcus aureus- MRSA</i>	258			0	0		0			0			0	100	100	98		100	62	13	89	92	43	43
<i>Staphylococcus coag. negative</i>	123			34	34		34			34			34			78		100	56	39	82	67	61	61
<i>Streptococcus pneumoniae</i> ¹	33	61						76		83	90		80					100		52	67	66		97
<i>Enterococcus faecium</i> ²	30	23	30											100	100	83 ³		40		7	33			
<i>Enterococcus faecalis</i> ²	57	100	100											100	100	81 ³		100		19	42			
<i>Strep. anginosus</i> grp (<i>S. milleri</i>)	62 ⁴	95								100														100
GRAM NEGATIVES																								
<i>Haemophilus influenzae</i>	56		80 ⁵																					
<i>Escherichia coli</i>	197		56		64	94	81	88	92	91	91	93	100			93	93				76	80	83	83
<i>Enterobacter cloacae</i> complex	54		0		0	78	0	0	76	70	94	76	100			96	96				89	91	97	98
<i>Klebsiella oxytoca</i>	36		0		44	75	30	74	94	75	92	75	100			100	100				89	97	100	100
<i>Klebsiella pneumoniae</i>	90		0		81	92	87	83	94	94	93	93	100			97	94				83	92	91	98
<i>Pseudomonas aeruginosa</i>	101					86			83		82	75	88			93	100						87	88
<i>Serratia marcescens</i>	44		0		0	77	0	0	84	91	94	89	100			98	84				9	98	84	93
<i>Stenotrophomonas maltophilia</i> ⁶	44								38													96		85

¹ non-meningitis breakpoints

² **Severe enterococcal infections** require combination therapy with (high-dose penicillin or high-dose ampicillin or vancomycin) PLUS (gentamicin or streptomycin) for bactericidal action. If susceptible, ampicillin is preferred over vancomycin.

³ **Synergy** predicted for therapy with penicillin, ampicillin or vancomycin combined with gentamicin.

⁴ 62 isolates tested for Penicillin, 32 isolates tested for Ceftriaxone & Levofloxacin

⁵ **Negative β-lactamase predicts susceptibility to ampicillin**

⁶ 2018 & 2019 data combined

For use by providers within D-H only. Please do not share with Pharmaceutical Representatives.